Related Experiment Video
Updated: May 29, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Radiodynamic Therapy Using 5-Aminolevulinic Acid as a New Treatment Option for Osteosarcoma: An In Vitro and In Vivo
Yuki Tanemura1, Tomoki Nakamura2, Yumi Matsuyama1
1Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
Anticancer Research
|May 27, 2026
Summary
5-aminolevulinic acid (5-ALA) radiodynamic therapy (RDT) effectively reduced osteosarcoma cell growth in lab studies and inhibited tumor volume in mice. This suggests 5-ALA RDT is a promising new treatment for osteosarcoma.
Area of Science:
- Oncology
- Biochemistry
- Radiotherapy
Background:
- 5-aminolevulinic acid (5-ALA) radiodynamic therapy (RDT) shows antitumor effects in various cancers.
- Its efficacy in bone and soft tissue sarcomas, including osteosarcoma, requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of 5-ALA RDT in osteosarcoma cell lines.
- To determine the potential of 5-ALA RDT as a therapeutic strategy for osteosarcoma.
Main Methods:
- In vitro studies used human (143B) and mouse (LM8) osteosarcoma cells treated with 5-ALA and X-ray irradiation.
- In vivo studies involved subcutaneous osteosarcoma xenografts in BALB/c mice, treated with irradiation alone or 5-ALA RDT.
- Tumor volume, cell viability, body weight, and behavior were monitored.
Main Results:
- 5-ALA RDT significantly inhibited osteosarcoma cell proliferation in vitro.
- In vivo, 5-ALA RDT markedly reduced tumor volume in mice compared to control and irradiation-only groups.
- No adverse effects on body weight or behavior were observed in treated mice.
Conclusions:
- 5-ALA RDT exhibits significant antitumor activity against osteosarcoma in vitro and in vivo.
- These findings support the potential of 5-ALA RDT as a viable therapeutic option for osteosarcoma treatment.
